CL2021003115A1 - Sales farmacéuticamente aceptables de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propil)amina y usos de las mismas - Google Patents
Sales farmacéuticamente aceptables de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propil)amina y usos de las mismasInfo
- Publication number
- CL2021003115A1 CL2021003115A1 CL2021003115A CL2021003115A CL2021003115A1 CL 2021003115 A1 CL2021003115 A1 CL 2021003115A1 CL 2021003115 A CL2021003115 A CL 2021003115A CL 2021003115 A CL2021003115 A CL 2021003115A CL 2021003115 A1 CL2021003115 A1 CL 2021003115A1
- Authority
- CL
- Chile
- Prior art keywords
- methanesulfonylphenoxy
- fluoro
- propyl
- amine
- ethyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- OSBPYFBXSLJHCR-UHFFFAOYSA-N n-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]propan-1-amine Chemical class CCCNCCOC1=CC(F)=CC(S(C)(=O)=O)=C1 OSBPYFBXSLJHCR-UHFFFAOYSA-N 0.000 title 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19176514 | 2019-05-24 | ||
| EP20166361 | 2020-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021003115A1 true CL2021003115A1 (es) | 2022-09-30 |
Family
ID=70682855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021003115A CL2021003115A1 (es) | 2019-05-24 | 2021-11-24 | Sales farmacéuticamente aceptables de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propil)amina y usos de las mismas |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12275694B2 (https=) |
| EP (2) | EP3976581B1 (https=) |
| JP (1) | JP7623958B2 (https=) |
| KR (1) | KR102892833B1 (https=) |
| CN (1) | CN113853369B (https=) |
| AU (1) | AU2020286003B2 (https=) |
| BR (1) | BR112021023563A2 (https=) |
| CA (1) | CA3140805A1 (https=) |
| CL (1) | CL2021003115A1 (https=) |
| CO (1) | CO2021016556A2 (https=) |
| DK (1) | DK3976581T3 (https=) |
| ES (1) | ES2970361T3 (https=) |
| FI (1) | FI3976581T3 (https=) |
| IL (1) | IL288271B2 (https=) |
| JO (1) | JOP20210312A1 (https=) |
| MX (1) | MX2021014271A (https=) |
| PH (1) | PH12021552844A1 (https=) |
| PL (1) | PL3976581T3 (https=) |
| PT (1) | PT3976581T (https=) |
| SG (1) | SG11202112165QA (https=) |
| WO (1) | WO2020239568A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021023563A2 (pt) | 2019-05-24 | 2022-01-04 | Integrative Res Laboratories Sweden Ab | Sais farmaceuticamente aceitáveis de [2-(3-fluoro-5-metano-sulfonilfenóxi)etil](propil) amina e usos dos mesmos |
| TW202233169A (zh) * | 2020-11-10 | 2022-09-01 | 瑞典商瑞典綜合研究實驗室公司 | 包含[2-(3-氟-5-甲磺醯苯氧基)乙基](丙基)胺之醫藥上可接受鹽類的醫藥組成物、及治療帕金森氏症的藥物及所述醫藥組成物的用途 |
| EP4577201A1 (en) * | 2022-08-24 | 2025-07-02 | Alkem Laboratories Limited | Mesdopetam compositions |
| EP4590657A1 (en) | 2022-09-21 | 2025-07-30 | Assia Chemical Industries Ltd. | Solid state forms of mesdopetam and salts therof |
| GB202312055D0 (en) | 2023-08-07 | 2023-09-20 | Ipsen Biopharm Ltd | Pharmaceutical compositions |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51123821A (en) | 1975-04-18 | 1976-10-28 | Nippon Kayaku Co Ltd | An algicide and protective agent |
| US4128574A (en) * | 1976-10-04 | 1978-12-05 | General Electric Company | Method for making organic polycarboxylic acids |
| GB8823405D0 (en) | 1988-10-05 | 1988-11-09 | Erba Carlo Spa | Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines |
| ATE210657T1 (de) | 1994-10-14 | 2001-12-15 | Merck Patent Gmbh | Zns wirksames (r)-(-)-2-(5-(4-fluorophenyl)-3- pyridylmethylaminomethyl)chroman |
| SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| DOP2001000189A (es) | 2000-06-30 | 2002-03-30 | Pfizer Prod Inc | Benzofenonas y sulfonas como inhibidores de la captación de glicina |
| JP2006193494A (ja) | 2005-01-17 | 2006-07-27 | Dainippon Ink & Chem Inc | 4級アンモニウム系化合物を有効成分とする心臓疾患治療剤 |
| US20100069346A1 (en) | 2005-06-23 | 2010-03-18 | Sara Holmqvist | New Azetidine Derivatives as Neurokinin Receptor Antagonists for the Treatment of Gastrointestinal Diseases |
| JP5210637B2 (ja) | 2005-11-29 | 2013-06-12 | キッセイ薬品工業株式会社 | 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| WO2007072041A1 (en) | 2005-12-23 | 2007-06-28 | Astex Therapeutics Limited | Therapeutic compounds |
| ATE534638T1 (de) * | 2006-02-15 | 2011-12-15 | Ms Science Corp | Piperazin-derivate |
| CA2687721A1 (en) * | 2007-06-08 | 2008-12-18 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| TW200932225A (en) * | 2007-12-14 | 2009-08-01 | Lundbeck & Co As H | 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine |
| JP2011519839A (ja) | 2008-04-29 | 2011-07-14 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | ドーパミン神経伝達のモジュレーター |
| MX2010011724A (es) | 2008-04-29 | 2010-11-30 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
| EP2271638B1 (en) | 2008-04-29 | 2011-08-31 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Modulators of dopamine neurotransmission |
| EP2699543B1 (en) * | 2011-04-19 | 2016-03-02 | Integrative Research Laboratories Sweden AB | Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| CN117304079A (zh) | 2016-02-08 | 2023-12-29 | 默克专利股份有限公司 | N-(4,5-双甲磺酰基-2-甲基苯甲酰基)胍盐酸盐和n-(4,5-双甲磺酰基-2-甲基苯甲酰基)胍盐的结晶变体 |
| EP3625213B1 (en) | 2017-05-19 | 2023-03-08 | Integrative Research Laboratories Sweden AB | (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine fumarate, a process for its preparation and uses thereof |
| ES2874628T3 (es) * | 2017-08-07 | 2021-11-05 | Suven Life Sciences Ltd | Compuestos de fluoropiperidina como antagonistas puros del receptor 5-HT6 |
| WO2020110128A1 (en) | 2018-11-29 | 2020-06-04 | Prilenia Neurotherapeutics Ltd. | Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia |
| BR112021023563A2 (pt) | 2019-05-24 | 2022-01-04 | Integrative Res Laboratories Sweden Ab | Sais farmaceuticamente aceitáveis de [2-(3-fluoro-5-metano-sulfonilfenóxi)etil](propil) amina e usos dos mesmos |
-
2020
- 2020-05-20 BR BR112021023563A patent/BR112021023563A2/pt unknown
- 2020-05-20 ES ES20725728T patent/ES2970361T3/es active Active
- 2020-05-20 SG SG11202112165QA patent/SG11202112165QA/en unknown
- 2020-05-20 DK DK20725728.8T patent/DK3976581T3/da active
- 2020-05-20 KR KR1020217037818A patent/KR102892833B1/ko active Active
- 2020-05-20 EP EP20725728.8A patent/EP3976581B1/en active Active
- 2020-05-20 US US17/612,902 patent/US12275694B2/en active Active
- 2020-05-20 CN CN202080036829.0A patent/CN113853369B/zh active Active
- 2020-05-20 EP EP23190702.3A patent/EP4292653B1/en active Active
- 2020-05-20 PT PT207257288T patent/PT3976581T/pt unknown
- 2020-05-20 PL PL20725728.8T patent/PL3976581T3/pl unknown
- 2020-05-20 AU AU2020286003A patent/AU2020286003B2/en active Active
- 2020-05-20 WO PCT/EP2020/064046 patent/WO2020239568A1/en not_active Ceased
- 2020-05-20 MX MX2021014271A patent/MX2021014271A/es unknown
- 2020-05-20 PH PH1/2021/552844A patent/PH12021552844A1/en unknown
- 2020-05-20 CA CA3140805A patent/CA3140805A1/en active Pending
- 2020-05-20 FI FIEP20725728.8T patent/FI3976581T3/fi active
- 2020-05-20 IL IL288271A patent/IL288271B2/en unknown
- 2020-05-20 JP JP2021569359A patent/JP7623958B2/ja active Active
-
2021
- 2021-11-24 CL CL2021003115A patent/CL2021003115A1/es unknown
- 2021-11-24 JO JOP/2021/0312A patent/JOP20210312A1/ar unknown
- 2021-12-06 CO CONC2021/0016556A patent/CO2021016556A2/es unknown
-
2025
- 2025-03-14 US US19/080,430 patent/US20250243155A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021016556A2 (es) | Sales farmacéuticamente aceptables de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propil)amina y usos de las mismas | |
| PE20210919A1 (es) | Sales de un inhibidor de fgfr | |
| CO2019012359A2 (es) | Oxadiazoles fungicidas | |
| MX2020013726A (es) | Compuestos antagonistas de pcsk9. | |
| CO2021005568A2 (es) | Tolilo sustituido como fungicidas | |
| DOP2021000254A (es) | Compuestos de pirrolidina | |
| BR112021022536A2 (pt) | Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo | |
| BR112019000026A2 (pt) | sais de ácido diorganilfosfínico, método para sua produção e seu uso | |
| MX2017003945A (es) | Preparacion farmaceutica. | |
| BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| BR112016013618A8 (pt) | derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos | |
| CO2021004873A2 (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| CO2021009309A2 (es) | Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo | |
| CO2021002940A2 (es) | Pirazoles fungicidas sustituidos con nitroanilino | |
| MX2018010177A (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida. | |
| AR109168A1 (es) | Sales de derivados de 2,6-dimetilpirimidona y sus usos | |
| CL2025002938A1 (es) | Compuestos heterociclos y uso como fungicidas. | |
| DOP2020000088A (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk2. | |
| AR126196A1 (es) | Proceso para preparar inhibidores de egfr | |
| MX390507B (es) | Compuestos de amida y su uso. | |
| MX2021000611A (es) | Una sal de xinafoato de un compuesto inhibidor de jak. | |
| UY38567A (es) | Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico | |
| CO2022008127A2 (es) | Procesos e intermediario para la preparación de oxetan-2-ilmetanamina | |
| MX381611B (es) | Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, método para prepararlos y composición farmacéutica que los contiene. |